Molecular structure of Combretastatin A4 Phosphate Disodium Salt, CAS Number: 168555-66-6
Combretastatin A4 Phosphate Disodium Salt (CAS 168555-66-6)
Alternate Names:
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol 1-(Dihydrogen phosphate) Sodium Salt CA 4P
Application:
Combretastatin A4 Phosphate Disodium Salt is A microtubule depolymerizing molecule
CAS Number:
168555-66-6
Molecular Weight:
440.29
Molecular Formula:
C18H19Na2O8P
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Combretastatin A4 Phosphate Disodium Salt is a phosphorylated microtubule depolymerizing molecule which induces tumor necrosis by regression of unstable nascent tumor neovessels. Studies suggest that Combretastatin A4 Phosphate Disodium Salt selectively inhibits endothelial tumor cells via disrupting VE-cadherin (vascular endothelial-cadherin). In addition, Combretastatin A4 Phosphate Disodium Salt can increase the permeability of endothelial cells while inhibiting their migration and suppress capillary tube formation via disruption of VE-cadherin. Furthermore, Combretastatin A4 Phosphate Disodium Salt can change the morphology of endothelial cells by altering their tubulin cytoskeleton.
Combretastatin A4 Phosphate Disodium Salt (CAS 168555-66-6) References
- Targeting tumour vasculature: the development of combretastatin A4. | Griggs, J., et al. 2001. Lancet Oncol. 2: 82-7. PMID: 11905799
- Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. | Rojiani, AM., et al. 2002. Acta Oncol. 41: 98-105. PMID: 11990526
- Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. | Wildiers, H., et al. 2004. Eur J Cancer. 40: 284-90. PMID: 14728944
- Combretastatin A4 phosphate. | West, CM. and Price, P. 2004. Anticancer Drugs. 15: 179-87. PMID: 15014350
- Combretastatin A4 phosphate: background and current clinical status. | Young, SL. and Chaplin, DJ. 2004. Expert Opin Investig Drugs. 13: 1171-82. PMID: 15330748
- Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. | Vincent, L., et al. 2005. J Clin Invest. 115: 2992-3006. PMID: 16224539
- Combretastatin A4 phosphate: a novel vascular disrupting agent. | Nagaiah, G. and Remick, SC. 2010. Future Oncol. 6: 1219-28. PMID: 20799867
- Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P). | Signoretto, E., et al. 2016. Cell Physiol Biochem. 38: 969-81. PMID: 26938611
- Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status. | Jaroch, K., et al. 2016. Pharmacol Rep. 68: 1266-1275. PMID: 27686966
- Enhanced local cancer therapy using a CA4P and CDDP co-loaded polypeptide gel depot. | Yu, S., et al. 2019. Biomater Sci. 7: 860-866. PMID: 30698593
Inhibitor of:
Tubulin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Combretastatin A4 Phosphate Disodium Salt, 5 mg | sc-211124 | 5 mg | $360.00 |